Proteomics Peptides & KitsPeptide sets and pools, as well as assay standardization kits are available with stable isotope labeled or unlabeled proteotypic peptides for mass-spectrometry based proteomics such as MRM assays.

Chelate Peptides (DOTA)DOTA is linked to molecules that have affinity for various structures (e.g. somatostatin receptors in neuroendocrine tumors). The resulting compounds can be bound to radionuclided and are used with a number of radioisotopes in cancer therapy and diagnosis

Immunology Standards & ControlsStandards and controls for reproducible T-cell assays such as ELISPOT and multimer assays. We offer a large variety of positive and negative control peptide pools for antigen specific T cell stimulation as well as kit to produce TCR-engineered reference samples for performance control.

Antigen PeptidesAntigen peptides represent specific epitopes for stimulation of T cells in T cell assays such as ELISPOT. We offer the corresponding MHC multimer for each antigen peptide. Antigens from different pathogens are available as well as tumor associated antigens.

Cosmetic PeptidesCosmetic Peptides such as Lysine and Cysteine Peptide are used for DPRA (Direct Peptide Reactivity Assay) for Skin Sensitization Testing. The DPRA measures the reaction of a chemical with synthetic peptides containing Cysteine (Ac‑RFAACAA‑COOH) or Lysine (Ac‑RFAAKAA‑COOH) to assess its sensitization potency. For research use only!

Novel Small Molecule Bradykinin B2 Receptor Antagonists

Gibson et al., J. Med. Chem. (2009) - PMID: 19552431

Blockade of the bradykinin B(2) receptor provides therapeutic benefit in hereditary angioedema (HAE) and potentially in many other diseases. Herein, we describe the development of highly potent B(2) receptor antagonists with a molecular weight of approximately 500 g/mol. First, known quinoline-based B(2) receptor antagonists were stripped down to their shared core motif 53, which turned out to be the minimum pharmacophore. Targeted modifications of 53 resulted in the highly water-soluble lead compound 8a. Extensive exploration of its structure-activity relationship resulted in a series of highly potent B(2) receptor antagonists, featuring a hydrogen bond accepting functionality, which presumably interacts with the side chain of Asn-107 of the B(2) receptor. Optimization of the microsomal stability and cytochrome P450 inhibition eventually led to the discovery of the highly potent and orally available B(2) receptor antagonist 52e (JSM10292), which showed the best overall properties.